SCHEMBL20135135

SCHEMBL20135135

Cc1cnc(N2CCN(C(=O)c3ccc(C4(C5CCC5)NC(=O)NC4=O)cc3)CC2)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
ADAMTS5 Q9UNA0 4/20 0.38
KDM4E B2RXH2 1/20 0.37
ADAM17 P78536 2/20 0.37
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
GBA1 P04062 1/20 0.36
CFTR P13569 2/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 2/20 0.35
TNF P01375 1/20 0.35
SLC6A7 Q99884 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688916 1.00 ALDH1A1 (0.38) ALDH1A1ADAMTS5KDM4EADAM17MMP2
SCHEMBL29688749 0.96 ADAMTS5 (0.40) ALDH1A1ADAMTS5KDM4EADAM17MMP2
SCHEMBL20135181 0.96 ADAMTS5 (0.40) ALDH1A1ADAMTS5KDM4EADAM17MMP2
SCHEMBL29688853 0.92 ADAM17 (0.37) ALDH1A1ADAMTS5KDM4EADAM17LMNA
SCHEMBL20135058 0.92 ADAM17 (0.37) ALDH1A1ADAMTS5KDM4EADAM17LMNA
SCHEMBL29688813 0.91 SLC6A7 (0.38) ALDH1A1ADAMTS5KDM4EADAM17MMP2
SCHEMBL20134916 0.91 SLC6A7 (0.38) ALDH1A1ADAMTS5KDM4EADAM17MMP2
SCHEMBL20135138 0.87 SLC6A7 (0.37) ALDH1A1ADAMTS5KDM4EADAM17MMP2
SCHEMBL29688969 0.87 SLC6A7 (0.37) ALDH1A1ADAMTS5KDM4EADAM17MMP2
SCHEMBL20135609 0.87 ADAMTS5 (0.39) ALDH1A1ADAMTS5ADAM17MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ALDH1A1 584/4885ADAMTS5 23/4885KDM4E 725/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ALDH1A1 610/4885ADAMTS5 25/4885KDM4E 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.